Skip to main content
. 2022 Jun 28;41(3):541–554. doi: 10.1200/JCO.21.02698

FIG 5.

FIG 5.

(A) rwTTNT and OS in the ASCT-eligible cohort by ASCT status (yes v no) in the Flatiron cohort; (B) PFS and OS in the validation cohort. Median OS should be interpreted with caution as it was reached when few patients were still at risk. ASCT, autologous stem-cell transplant; HR, hazard ratio; NE, not estimable; NR, not reached; OS, overall survival; PFS, progression-free survival; rwTTNT, real-world time to next treatment.